+

WO2001005992A1 - Vecteurs de virus , preparations, utilisations - Google Patents

Vecteurs de virus , preparations, utilisations Download PDF

Info

Publication number
WO2001005992A1
WO2001005992A1 PCT/GB2000/002739 GB0002739W WO0105992A1 WO 2001005992 A1 WO2001005992 A1 WO 2001005992A1 GB 0002739 W GB0002739 W GB 0002739W WO 0105992 A1 WO0105992 A1 WO 0105992A1
Authority
WO
WIPO (PCT)
Prior art keywords
promoter
gene
responsive
mutant virus
virus
Prior art date
Application number
PCT/GB2000/002739
Other languages
English (en)
Inventor
Michael Keith Howard
Original Assignee
Cantab Pharmaceuticals Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Pharmaceuticals Research Limited filed Critical Cantab Pharmaceuticals Research Limited
Priority to AU60005/00A priority Critical patent/AU6000500A/en
Publication of WO2001005992A1 publication Critical patent/WO2001005992A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region

Definitions

  • This invention relates to viral mutants, and to materials and methods applicable to their production and use, for example as vectors and/or vaccines.
  • the invention extends to corresponding nucleotide sequence constructs of viral genes with modified promoters, to cell lines applicable for the culture of such viruses, and to pharmaceutical preparations of such viruses and their use.
  • viruses are known for purposes including use as gene delivery vectors and/or as vaccines, see for example prior specifications WO 92/05263, WO 94/21 807, and WO 96/26267 (Cantab Pharmaceuticals: Inglis et al) ; and WO 96/04395 (Lynxvale Ltd: P Speck) and the documentary references mentioned in each of them.
  • a mutant virus having modified gene promoter(s) so as to genetically disable the virus in the absence of a heterologous transcription factor. 'Genetically disabled' means that the virus, though able to infect a host cell, does not lead to the production of infectious new virus particles as a result of that infection.
  • a gene promoter of the ICP4 or ICP27 gene is at least partly modified so that expression of the gene is of substantially reduced or zero responsiveness to the normal VP16-host-cell-factor transcription complex.
  • the invention provides a nucleotide sequence construct comprising an essential viral gene operatively linked to a promoter that is responsive to a heterologous transcription factor.
  • the promoter is also non-responsive to homologous transcription factors.
  • Essential viral gene' means a viral gene that is essential for the production of infectious new viral progeny when the wild-type virus from which the gene originates infects a normal host cell.
  • 'Normal host cell' means a cell which is not a recombinant cell and which is of a cell type that can normally be infected by the wild-type virus from which the gene comes, with the production of infectious viral progeny, e.g. infectious new virus particles.
  • Heterologous transcription factor' will usually mean a factor capable of mediating gene transcription in cells other than normal host cells, but not of mediating transcription either of genes of normal host cells, or of genes of the wild-type virus from which the essential viral gene comes; in any event the desired result, as will be apparent from the remainder of the description herein, is that the heterologous transcription factor and the modified gene promoter included in the mutant virus according to the invention are arranged to match each other so that the modified promoter is responsive to the heterologous transcription factor, but the modified promoter has inappreciable or zero responsiveness to any of the transcription factors normally present in a normal host cell when infected with a virus of the parental type from which the mutant virus according to the invention has been derived, thus leading to genetic disablement of the mutant virus in the absence of the heterologous transcription factor.
  • a transcription factor normally present in a normal host cell infected by the parental virus type is the VP1 6-host-cell factor complex already mentioned, and an example of modified promoter as described below is unresponsive to that normal host cell transcription factor, but responsive to an example of an abnormal transcription factor based on Gal4 as described below.
  • 'Homologous transcription factor' means a factor capable of mediating transcription of genes of normal host cells, and/or of genes of the wild-type virus from which the essential viral gene comes.
  • the invention provides a mutant virus comprising a modified gene promoter operably linked to an essential viral gene, wherein the modified promoter is substantially non-responsive to normal virus and host transcription factors but is responsive to a heterologous transcription factor, so that said mutant virus is genetically disabled in the absence of said heterologous transcription factor.
  • Mutant viruses according to examples of the invention can be derived from herpes simplex virus type 1 or 2, or from other human or veterinary herpesviruses, and they can for example have additional genetic disability, e.g. the complete deletion of an essential late viral gene such as an essential glycoprotein gene, for example the HSV gH gene, and they can carry heterologous genes for delivery to a target cell, e.g. using methods referred to for example in WO 92/05263, WO 94/21 807, and WO 96/26267.
  • mutant virus is derived from HSV1 or HSV2, and is to be cultured for production purposes on a complementing cell line derived from
  • the ICP22 gene can be deleted without being complemented in the Vero-derived producer cell line.
  • the gene promoter of the ICP4 gene has been modified to include an exogenous transcription element that is responsive to a transcription factor not normally encoded by HSV or by a normal host cell.
  • an exogenous (heterologous) promoter element is a Gal4 promoter element.
  • the Gal4 fungal transcriptional activator protein is described for example in J C Corton et al (J Biol Chem, 1 998, 273(22) pp 1 3776- 1 3780) .
  • Nucleotide sequences respectively encoding Gal4, and an alternative useful transcriptional activator protein which is a fusion involving Gal4 and a domain of VP 1 6, can be obtained in practice as mentioned herein below.
  • the UAS (enhancer) DNA sequence for conferring responsiveness to Gal4 protein upon a gene promoter is described for example in S Walker et al, (Mol Cell Biol 1 993, 1 3(9) : pp 5233-5244, and in further references given below.
  • any number of copies of the UAS sequence can be present in the gene promoter to be affected.
  • the transcriptional activator protein is Gal4 itself, it is very preferable to use a multiple number of copies of the UAS sequence in the gene promoter to be affected, e.g. at least 4.
  • a Gal4-VP1 6 hybrid fusion protein suitable for use in connection with the present invention can be constructed in a generally similar fashion with the Gal4 DNA binding domain sequence (pMDNA-BD plasmid) and a sequence encoding the VP1 6 activation domain (from Clontech plasmid pVP1 6) . Both plasmids are available in the mammalian Matchmaker (cat. K1 602- 1 ) two- hybrid assay kit.)
  • a gene encoding Gal4 or encoding the Gal4-VP1 6(domain) fusion protein mentioned herein can be used to make a transfected complementing producer-host cell line for viral vectors according to examples of the invention.
  • an essential herpesviral gene e.g. an immediate early gene, e.g. ICP27 and/or ICP4 of HSV1 or HSV2
  • a promoter that is responsive to Gal4 or other heterologous transcription factor can be operatively linked to a promoter that is responsive to Gal4 or other heterologous transcription factor.
  • the construct can be such that the normal TAATGARAT-containing promoter element normally associated with the herpesviral immediate early gene is replaced with a Gal4 response element. This replacement can also make the thus-modified promoter non-responsive to the (homologous) transcription factor complex VP1 6-Oct1 -HCF.
  • the ICP4 gene can have a modified gene promoter as described above, and the ICPO and ICP27 genes can also have a similarly modified promoter.
  • the ICPO and ICP27 genes can have promoters that have been modified to allow the genes to express as early genes but not as immediate- early genes in the herpesviral life-cycle. This in turn can be done e.g. by the deletion of each TAATGARAT-containing promoter element normally associated with the respective immediate early gene, or, by the replacement of the promoter by another promoter that confers early-expression kinetics, such as the promoter from the rabbit beta-giobin gene.
  • ICP4, ICP22 and ICP27 genes have been modified at least so as to lose all or substantially all of their normal responsiveness to the VP1 6-host-cell-factor transcription complex.
  • embodiments of the invention include mutant herpes viruses in which the modified promoter(s) are for essential immediate- early viral genes, e.g. ICP4 or ICP27 gene.
  • the promoter modification can have been produced by modification of a native virus promoter, and can comprise an inserted heterologous promoter element.
  • the modification can be carried out by deleting the TAATGARAT-containing element of a normal immediate-early viral gene promoter and inserting a promoter element that renders the promoter responsive to a heterologous promoter.
  • the virus can have had the transactivation domain of the VP1 6 gene deleted as a further mutation.
  • the inserted promoter element can be one that renders the promoter responsive to Gal4 transcriptional activator protein itself, or to a
  • Gal4-containing transcription factor such as a fusion protein comprising sequences of Gal4 transcriptional activator protein and of herpesviral VP1 6 protein.
  • each native promoter to be made responsive to the heterologous transcription factor can be replaced by a synthetic or semi-synthetic promoters containing (a) minimal promoter elements that would give zero or essentially negligible functional protein expression in the absence of heterologous transcription factor, e.g. a TATA-box and optionally further promoter element(s) such as Sp 1 sequence(s); along with (b) a response element corresponding to the chosen heterologous transcription factor, e.g. UAS (enhancer) sequence element(s) in the case of Gal4 or Gal4-VP1 6 fusion protein as the heterologous transcription factor.
  • UAS encodehancer
  • Such mutant viruses are genetically disabled in the absence of a heterologous transcription factor, e.g. the Gal4 factor in the case mentioned.
  • Genetic disability here means at least that the virus is unable to give rise to infectious new virus particles when it infects a normal host cell.
  • the disability goes further, as in the case of the herpesvirus examples mentioned above, and the mutant virus of the example mentioned above cannot cause its viral DNA to replicate in a normal host cell, and/or (if it can enter latency) then cannot reactivate from latency, and/or cannot express immediate early gene products, either at all, and/or cannot express them from the latent state.
  • the ICP4 and ICP27 with promoters modified or substituted as already mentioned can be replaced with the modified ICP4 construct in the ICP27 locus and the modified ICP27 construct in the ICP4 locus.
  • This feature can bring additional security against the production of unwanted recombinants. Recombination with a wild-type virus would disable or destabilize any recombinant viral product.
  • Mutant viruses which comprise one or more modified or substituted promoters as described herein can also have further mutation, e.g. a deletion in one or more immediate-early genes, for example a deletion of an entire immediate-early gene, so that the mutant virus can only be grown on a cell- line which expresses the product of the deleted gene.
  • a mutant virus as mentioned above having modified promoters in respect of the ICP4 and ICP27 genes so that the modified promoters are insensitive to the normal transcription factors but sensitive to the Gal4 transcription factor, can have a phenotype that remains ICP4- negative and ICP27-negative in normal host cells, but can grow with wild-type kinetics in a complementing cell line providing a Gal4 transcription factor such as that described below.
  • ICP22 promoter and/or gene can also be deleted from such a virus, for additional disability in a normal host cell.
  • ICP22 is not necessary for culture of HSV on Vero cells, though if it is retained and its promoter modified as discussed herein, there can under some conditions be an advantage in virus yield from the producer cell culture.
  • viruses can be used as the basis of virus vectors for gene delivery, e.g. to carry and express useful genes in cells of a subject to be treated, e.g. a patient in need of the function of a gene product of the useful gene. This can for example be carried out in relation to the CNS of a subject of treatment.
  • Genes known per se for delivery e.g. tyrosine hydroxylase, can be inserted into the present mutant viruses for such purposes.
  • virus vectors are essentially non-toxic while still producible in good yield in a complementing cell line as described below.
  • the mutations described herein can also prevent expression and consequential cytotoxicity of the immediate-early genes if the vector has become latent within the CNS of a treated subject or patient.
  • HSV vectors including those based on HSV mutant in1814 (which lacks the trans-activating function of VP1 6) , all carry the risk that any remaining immediate-early genes can still be expressed subsequent to any cellular stimulus that is normally capable of inducing reactivation of latent HSV.
  • the transactivation domain of the VP1 6 gene in the vector can be useful also to delete the transactivation domain of the VP1 6 gene in the vector. This will have no effect on the growth of the vector in the complementing cell line, because preferably all the TAATGARAT-containing elements normally responsive to the VP1 6 transactivating domain have been replaced with elements responsive to the Gal4 transcription factor. However, the change can bring an additional safety factor, reducing any risk of reactivating any latent wild-type virus that may already be present in the CNS of a subject of treatment.
  • the present mutant viruses can be cultured, according to an aspect of the invention, in host cells made recombinant with a gene encoding and able to express the mentioned heterologous transcription factor.
  • the invention is also applicable to the production of defective viral vectors e.g. herpesvirus amplicons, which require a helper virus for their production.
  • the helper virus can be genetically disabled by the deletion or inactivation of an essential gene, e.g. an immediate early or early gene such as ICP4, ICP27 or ICP8, and a corresponding gene can be included in the defective vector and operatively linked to a promoter responsive to a heterologous transcription factor but not responsive to normal transcription factors of the infected host cell, e.g. as in US 5,928,91 3 (Efstathiou et al) .
  • These vectors and helper viruses can be used to generate e.g.
  • the defective vector is grown in the presence of helper virus which has had the essential gene deleted or inactivated, on a cell line which supplies the corresponding heterologous transcription factor.
  • a host cell suitable for culturing the mutant virus mentioned above is a Vero cell that has been made recombinant and expresses a gene encoding Gal4 transcription factor. It can be convenient to include also in the cell line a gene encoding a selectable marker such as neomycin resistance and responsive to the Gal4 transcription factor. Culture of the cell line in the presence of the selection factor e.g. neomycin can then be used to select for retention of the gene encoding the heterologous transcription factor.
  • the selection factor e.g. neomycin
  • virus vectors and nucleic acid constructs according to the present invention can be made using materials and nucleic acid sequences as indicated below, which are given for illustration and without intent to limit the scope of the invention.
  • Appendix A.1 gives the sequence of an ICP4-promoter-active sequence from HSV1 . This includes (where indicated) an oris sequence from [ * 1 to *2] (which may be dispensable in the present context); and within the promoter- active region a sphl site at *3, and EcoRI site at *4. The start site for transcription of ICP4 mRNA is at *5, and the start of the ICP4 coding sequence is at * 6. A corresponding expression construct for ICP4 can continue with the remainder of the (known) coding sequence of ICP4 protein continuing at the 3' end (omitted in A.1 for brevity).
  • a modified ICP4 promoter-active sequence for a modified HSV1 vector according to the present invention can be made on the basis of deleting the
  • TAATGARAT element using Sphl and EcoRI restriction enzymes to delete the sequence between the Sphl and EcoRI sites in the sequence of A.1 , and ligating in its place a number of copies, e.g. 1 -5, of a UAS sequence for binding gal4.
  • a resulting modified sequence, according to the invention, with 4 UAS copies (a 4x consensus Gal4 binding sequence) is shown in Appendix A.1 .1 which can likewise continue with the remainder of the coding sequence of the ICP4 protein.
  • the 4x consensus GAL4 binding sequence just referred to is (5'-3') :- CGGAAGACTC TCCTCCGAGC GGAAGACTCT CCTCCGAGCG GAAGACTCTC
  • CTCCGAGCGG AAGACTCTCC TCCGAG has been adapted from Walker et al. (Mol Cell Biol ( 1 993) 1 3(9) : pp 5233-5244) .
  • Gal4 responsive element (with a 5x repeat, i.e. containng five 1 7-nucleotide GAL4 binding elements) which can be used as an alternative to the 4x sequence just given, is
  • Appendix A.2 gives (5'-3') the sequence of an ICPO-promoter-active sequence from HSV1 . This includes (where indicated) the end of the ICP34.5 structural gene including the stop codon [ * 1 to *2] and a poly-A tail at * 3 (all of which should usually be left intact in the present context where ICP34.5 function is to be retained) ; and within the promoter-active region a stul site at *4, and sacll site at * 5, between which is a TAATGARAT-containing sequence.
  • the start of the ICPO coding sequence (containing exons and introns) is at * 6.
  • a corresponding expression construct for ICPO can continue with the remainder of the (known) coding sequence of ICPO protein continuing at the 3' end (omitted in A.2 for brevity).
  • a modified ICPO promoter-active sequence for a modified HSV1 vector according to an example of the present invention can be made on the basis of deleting the TAATGARAT element using stul and sacll restriction enzymes to delete the sequence between the indicated sites in the sequence of A.2, and ligating in its place a number of copies, e.g. 1 -5, of a UAS sequence for binding gal4.
  • Appendix A.3 gives (5'-3') the sequence of an ICP27-promoter-active sequence from HSV1 . This includes (where indicated) the last 5 codons of the UL53 structural gene (encoding essential glycoprotein gK) [ * 1 to *2] and the following 3-prime untranslated region to *3 (all which should usually be left intact in the present context where UL53 function is to be retained); and within the promoter region, BsaAI sites (immediately after *3 and at *4) , between which is a TAATGARAT-containing sequence. The start of the ICP27 coding sequence (containing exons and introns) is at * 5. ICP27- promoter-activity is considered to lie in the sequence between *4 and * 5.
  • a corresponding expression construct for ICP27 can continue with the remainder of the (known) coding sequence of ICP27 protein continuing at the 3' end (omitted in A.3 for brevity) .
  • a modified ICP27 promoter-active sequence for a modified HSV1 vector according to an example of the present invention can be made on the basis of deleting the TAATGARAT element(s) using BsaAI restriction enzyme to delete the sequence between the indicated sites in the sequence of A.3, and ligating in its place a number of copies, e.g. 1 -5, of a UAS sequence for binding gal4.
  • a resulting modified ICP27 promoter/expression sequence, according to the invention, with 4 UAS copies, is shown in Appendix A.3.1 which can likewise continue with the remainder of the coding sequence of the ICP27 protein.
  • the modification can be practised by (a) deleting the native copy of the ORF of the gene while leaving its promoter intact for the sake of the further function, and (b) inserting, at an ectopic location in the viral genome (e.g. the locus of a deleted essential viral gene in the case of a genetically disabled virus vector carrying such a deletion), the corresponding modified promoter linked to its respective ORF.
  • the accompanying Figure shows in diagrammatic form, as a plasmid map, a recombination plasmid for making an example of a mutant HSV1 virus according to the invention.
  • the ICP27 gene promoter is to be made unresponsive to its normal transcription factor but responsive instead to either Gal4 transcription factor or to a Gal4-VP1 6 fusion construct transcription factor.
  • the plasmid is based on a commercially available plasmid pSP73, via an intermediate plasmid pGTF1 which has been provided in per-se conventional manner with flanking sequences for the HSV1 ICP27 gene and promoter, i.e. with the UL52, UL53 and UL56 sequences, but which has deletions in respect of ICP27 (UL54) and nearly all of the (nonessential) UL55 sequence, leaving the polyadenylation signal normally associated with UL55 now attached to
  • the illustrated plasmid pGTF66 results from reinsertion of an ICP27 sequence with modified promoter, not in the normal ICP27 site, but placed instead downstream of the polyadenylation signal remaining from the UL55 sequence.
  • the ICP27 promoter is modifed in the manner generally described herein, by substituting for the TAATGARAT sequence a Gal4-responsive UAS signal.
  • a suitable example of a Gal4-responsive UAS signal sequence can be obtained and excised from a commercially available plasmid designated pGene/V5-His (version A, B or C) which is available as part of an inducible gene expression kit 'Gene Switch (TM) System' from Invitrogen Inc.
  • a virus according to an example of the invention can then be produced from recombination carried out in per-se known manner between this plasmid and a HSV1 genome, with selection based on ability to grow without ICP27 but with a requirement for a cell line that provides a Gal4-containing transcription factor.
  • the ICP27 gene promoter in the resulting virus is unresponsive to its normal transcription factor, but responsive instead to either Gal4 transcription factor or to a Gal4-VP1 6 fusion construct transcription factor.
  • the invention extends inter alia to DNA constructs as described herein, and to plasmids and other expression vectors, including mutant herpesviruses, that contain those constructs, e.g. mutant herpesviruses in which those constructs have been inserted in locations chosen to produce the operative relations described herein.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un virus mutant, par exemple un virus herpès, contenant un promoteur de gène modifié, par exemple un promoteur sensible à un facteur de transcription contenant Gal4, relié de façon opérable à un gène viral essentiel, par exemple un gène immédiat, à partir duquel le promoteur modifié est particulièrement non-réactif à un virus normal et aux facteurs de transcription hôte mais est réactif à un facteur de transcription hétérologue, par exemple Gal4 ou une fusion Gal4-VO16, de sorte que ledit virus mutant est génétiquement inapte en l'absence dudit facteur hétérologue de trancription. Le virus peut être utilisé comme un vecteur de distribution d'un gène hétérologue vers une cellule cible.
PCT/GB2000/002739 1999-07-16 2000-07-17 Vecteurs de virus , preparations, utilisations WO2001005992A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60005/00A AU6000500A (en) 1999-07-16 2000-07-17 Virus vectors and preparations and their uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9916702.5 1999-07-16
GBGB9916702.5A GB9916702D0 (en) 1999-07-16 1999-07-16 Virus vectors and preparations and their use

Publications (1)

Publication Number Publication Date
WO2001005992A1 true WO2001005992A1 (fr) 2001-01-25

Family

ID=10857359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002739 WO2001005992A1 (fr) 1999-07-16 2000-07-17 Vecteurs de virus , preparations, utilisations

Country Status (3)

Country Link
AU (1) AU6000500A (fr)
GB (1) GB9916702D0 (fr)
WO (1) WO2001005992A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429480B2 (en) 2005-01-10 2008-09-30 National Taiwan University Promoter sequences from WSSV immediate early genes and their uses in recombinant DNA techniques
JP2020503265A (ja) * 2016-11-17 2020-01-30 ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド メチル−ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003563A1 (fr) * 1990-08-15 1992-03-05 Akzo N.V. Procede de modification de la cellule, du tissu ou du tropisme hote d'un microorganisme, microorganismes de recombinaison ainsi obtenus et leurs applications medicales et veterinaires
WO1996039841A1 (fr) * 1995-06-07 1996-12-19 Georgetown University Replication du virus de l'herpes simplex specifique de cellule ou de tumeur
WO1998021350A1 (fr) * 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminution d'une expression genique virale par remplacement d'un promoteur

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003563A1 (fr) * 1990-08-15 1992-03-05 Akzo N.V. Procede de modification de la cellule, du tissu ou du tropisme hote d'un microorganisme, microorganismes de recombinaison ainsi obtenus et leurs applications medicales et veterinaires
WO1996039841A1 (fr) * 1995-06-07 1996-12-19 Georgetown University Replication du virus de l'herpes simplex specifique de cellule ou de tumeur
WO1998021350A1 (fr) * 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminution d'une expression genique virale par remplacement d'un promoteur

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIYATAKE S.-I. ET AL.: "Transcriptional targeting of herpes simplex virus for cell-specific replication.", JOURNAL OF VIROLOGY, vol. 71, no. 7, 1997, pages 5124 - 5132, XP002152492, ISSN: 0022-538X *
PRESTON C. M. ET AL: "Construction and characterization of herpes simplex virus type 1 mutants with conditional defects in immediate early gene expression.", VIROLOGY, vol. 229, no. 1, 1997, pages 228 - 239, XP002152493, ISSN: 0042-6822 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429480B2 (en) 2005-01-10 2008-09-30 National Taiwan University Promoter sequences from WSSV immediate early genes and their uses in recombinant DNA techniques
JP2020503265A (ja) * 2016-11-17 2020-01-30 ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド メチル−ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達
JP7106534B2 (ja) 2016-11-17 2022-07-26 ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達
JP2022137210A (ja) * 2016-11-17 2022-09-21 ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達
US11583564B2 (en) 2016-11-17 2023-02-21 Nationwide Children's Hospital, Inc. Intrathecal delivery of recombinant adeno-associated virus encoding Methyl-CpG binding protein 2

Also Published As

Publication number Publication date
AU6000500A (en) 2001-02-05
GB9916702D0 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
Cherrington et al. Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element
Samaniego et al. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27
Fink et al. Gene transfer to neurons using herpes simplex virus-based vectors
Glorioso et al. Development and application of herpes simplex virus vectors for human gene therapy
Lilley et al. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo
Leib et al. A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency
US6319703B1 (en) Recombinant virus vectors
US6821753B2 (en) Replication incompetent herpes viruses for use in gene therapy
EP1049769A2 (fr) Souches mutantes du virus de l'herpes et utilisations correspondantes
AU2001264862B2 (en) Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
Preston et al. Construction and characterization of herpes simplex virus type 1 mutants with conditional defects in immediate early gene expression
Neve et al. Overview of gene delivery into cells using HSV‐1‐based vectors
Marshall et al. Long-term transgene expression in mice infected with a herpes simplex virus type 1 mutant severely impaired for immediate-early gene expression
AU2001264862A1 (en) Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
Thomas et al. Equine herpesvirus 1 gene 12 can substitute for vmw65 in the growth of herpes simplex virus (HSV) type 1, allowing the generation of optimized cell lines for the propagation of HSV vectors with multiple immediate-early gene defects
Lilley et al. Herpes simplex virus vectors for the nervous system
Glorioso et al. Herpes simplex virus as a gene-delivery vector for the central nervous system
Fraefell et al. Herpes simplex virus type 1-based amplicon vector systems
US7262033B1 (en) Cell lines for the propagation of mutated herpes viruses
WO2001005992A1 (fr) Vecteurs de virus , preparations, utilisations
US20040248300A1 (en) Enhanced gene expression using vectors
Burton et al. Use of the herpes simplex viral genome to construct gene therapy vectors
US20040105844A1 (en) Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
Kasai et al. DNA-based methods to prepare helper virus-free herpes amplicon vectors and versatile design of amplicon vector plasmids
STEWART et al. Analysis of the basis for persistence of herpes simplex virus type 1 in undifferentiated U937 cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载